2024-present
CD8+ T cells cross-restricted by HLA-B*57 and HLA-E*01 recognize HIV Gag with different functional profiles. Maroney KJ, Rose MA, Oman AK, Chopra A, Hsieh HS, Derza Z, Waterworth R, Brockman MA, Kalams SA, Bansal A, Goepfert PA. JCI Insight. 2025 Dec 18;11(3):e189909. doi: 10.1172/jci.insight.189909. eCollection 2026 Feb 9.
Twelve-month trajectories of depressive symptoms and associated socio-structural factors among adolescents and young adults in Soweto and Durban, South Africa. Pakhomova TE, Beksinska M, Dietrich JJ, Salway TJ, Gadermann A, Closson K, Rowlands A, Jesson J, Ndung'u T, Brockman M, Nduna M, Vermaak S, Smit J, Kaida A. J Affect Disord. 2026 Jan 15;393(Pt B):120409. doi: 10.1016/j.jad.2025.120409. Epub 2025 Oct 10.
Prolonged non-suppressible viremia sustained by a clonally expanded, genomically defective provirus with an immune-evasive HIV protein expression profile. Omondi FH, Sang Y, Mwimanzi F, Cheung PK, Derza Z, Dong W, Barad E, Anderson K, Mysak V, Lima VD, Hull M, Brumme CJ, Harris M, Montaner JSG, Guillemi S, Brockman MA, Brumme ZL. bioRxiv [Preprint]. 2025 May 16:2025.05.16.654538. doi: 10.1101/2025.05.16.654538.
Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study. Sohai DK, Keller MD, Hanley PJ, Hoq F, Kukadiya D, Datar A, Reynolds E, Copertino DC, Lazarski C, McCann CD, Tanna J, Shibli A, Lang H, Zhang A, Chansky PA, Motta C, Huynh TT, Dwyer B, Wilson A, Lynch R, Mota TM, Conce Alberto WD, Brumme ZL, Kinloch NN, Cruz CRY, MacLaren Ehui L, Henn S, Brad Jones R, Bollard CM. Nat Commun. 2025 May 15;16(1):4510. doi: 10.1038/s41467-025-59810-2.
Investigation of Integrase Inhibitor Resistance Mutations in gp41 in Clinical Samples. Sudderuddin H, Dang Z, Watson B, Atkinson K, Le A, Sereda P, Brumme ZL, Brumme CJ. J Acquir Immune Defic Syndr. 2025 May 13. doi: 10.1097/QAI.0000000000003694.
Genetic determinants of HIV-1 subtype C Nef-mediated SERINC3 down-regulation. Samlall N, Reddy T, Ismail N, Brockman MA, Brumme ZL, Ndung'u T, Mann JK. Virol J. 2025 Apr 8;22(1):94. doi: 10.1186/s12985-025-02705-x.
Computational and Population-Based HLA Permissiveness to HIV Drug Resistance-Associated Mutations. Mahmud R, Krullaars Z, van Osch J, Rickett D, Brumme ZL, Hensley KS, Rokx C, Gruters RA, van Kampen JJA, Mesplède T. Pathogens. 2025 Feb 20;14(3):207. doi: 10.3390/pathogens14030207.
A simple phylogenetic approach to analyze hypermutated HIV proviruses reveals insights into their dynamics and persistence during antiretroviral therapy. Shahid A, Jones BR, Duncan MC, MacLennan S, Dapp MJ, Kuniholm MH, Aouizerat B, Archin NM, Gange S, Ofotokun I, Fischl MA, Kassaye S, Goldstein H, Anastos K, Joy JB, Brumme ZL. Virus Evol. 2024 Nov 11;11(1):veae094. doi: 10.1093/ve/veae094. eCollection 2025.
Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir. Rai MA, Blazkova J, Kardava L, Justement JS, Shi V, Manning MR, Shahid A, Dong W, Kennedy BD, Sewack AB, Higgins J, Buckner CM, Gittens K, West RE 3rd, Devanathan AS, Mangusan R, Lurain K, Ramaswami R, Yarchoan R, Sneller MC, Pau AK, Brumme ZL, Moir S, Chun TW. Nat Med. 2025 Feb;31(2):427-432. doi: 10.1038/s41591-024-03357-0. Epub 2025 Jan 3.
HIV-1 subtype A1, D, and recombinant proviral genome landscapes during long-term suppressive therapy. Lee GQ, Khadka P, Gowanlock SN, Copertino DC Jr, Duncan MC, Omondi FH, Kinloch NN, Kasule J, Kityamuweesi T, Buule P, Jamiru S, Tomusange S, Anok A, Chen Z, Jones RB, Galiwango RM, Reynolds SJ, Quinn TC, Brumme ZL, Redd AD, Prodger JL. Nat Commun. 2024 Jul 2;15(1):5480. doi: 10.1038/s41467-024-48985-9.
No detectable differences in Nef-mediated downregulation of HLA-I and CD4 molecules among HIV-1 group M lineages circulating in Cameroon, where the pandemic originated. Sonela N, Mann J, Godwe C, Goni OH, Tchakoute M, Nkoue N, de Oliveira T, Brockman MA, Brumme ZL, Ndung'u T, Tongo M. Front Virol. 2024 May 29;4:fviro.2024.1379217. doi: 10.3389/fviro.2024.1379217.
Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study. Costiniuk CT, Lee T, Singer J, Galipeau Y, Arnold C, Langlois MA, Needham J, Jenabian MA, Burchell AN, Samji H, Chambers C, Walmsley S, Ostrowski M, Kovacs C, Tan DHS, Harris M, Hull M, Brumme ZL, Lapointe HR, Brockman MA, Margolese S, Mandarino E, Samarani S, Lebouché B, Angel JB, Routy JP, Cooper CL, Anis AH; COVAXHIV Study Group. Vaccines (Basel). 2024 Apr 23;12(5):447. doi: 10.3390/vaccines12050447.
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy. Datwani S, Kalikawe R, Waterworth R, Mwimanzi FM, Liang R, Sang Y, Lapointe HR, Cheung PK, Omondi FH, Duncan MC, Barad E, Speckmaier S, Moran-Garcia N, DeMarco ML, Hedgcock M, Costiniuk CT, Hull M, Harris M, Romney MG, Montaner JSG, Brumme ZL, Brockman MA. Viruses. 2024 Apr 24;16(5):661. doi: 10.3390/v16050661.
Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting "block and lock" treatment strategies. Horvath RM, Brumme ZL, Sadowski I. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0107223. doi: 10.1128/aac.01072-23. Epub 2024 Feb 6.
Comparison of Omicron breakthrough infection versus monovalent SARS-CoV-2 intramuscular booster reveals differences in mucosal and systemic humoral immunity. Nantel S, Sheikh-Mohamed S, Chao GYC, Kurtesi A, Hu Q, Wood H, Colwill K, Li Z, Liu Y, Seifried L, Bourdin B, McGeer A, Hardy WR, Rojas OL, Al-Aubodah TA, Liu Z, Ostrowski MA, Brockman MA, Piccirillo CA, Quach C, Rini JM, Gingras AC, Decaluwe H, Gommerman JL. Mucosal Immunol. 2024 Apr;17(2):201-210. doi: 10.1016/j.mucimm.2024.01.004. Epub 2024 Jan 24.
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size. Duncan MC, Omondi FH, Kinloch NN, Lapointe HR, Speckmaier S, Moran-Garcia N, Lawson T, DeMarco ML, Simons J, Holmes DT, Lowe CF, Bacani N, Sereda P, Barrios R, Harris M, Romney MG, Montaner JSG, Brumme CJ, Brockman MA, Brumme ZL. AIDS. 2024 Jul 1;38(8):1120-1130. doi: 10.1097/QAD.0000000000003841. Epub 2024 Jan 22.
The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time. Shahid A, MacLennan S, Jones BR, Sudderuddin H, Dang Z, Cobarrubias K, Duncan MC, Kinloch NN, Dapp MJ, Archin NM, Fischl MA, Ofotokun I, Adimora A, Gange S, Aouizerat B, Kuniholm MH, Kassaye S, Mullins JI, Goldstein H, Joy JB, Anastos K, Brumme ZL; MACS/WIHS combined cohort study (MWCSS). J Virol. 2024 Feb 20;98(2):e0165523. doi: 10.1128/jvi.01655-23. Epub 2024 Jan 12.